BUSINESS METHOD TO TREAT AND/OR PREVENT A GASTRIC ACID DISORDER WITH A PROTON PUMP INHIBITOR (PPI) AND A CHOLINERGIC AGONIST TO INDUCE RAPID ONSET OF PPI ACTION WITH OR WITHOUT FOOD

Pharmaceutical proton pump inhibitor (PPI) medications and methods are disclosed for preventing and/or treating gastrointestinal disorders characterized by abnormalities in gastric acid secretion at anytime of the day or night without th...

WM Michael，LR Brown，PJ Manso

Oral pharmaceutical dosage forms comprising an inhibitor of proton pump and an antacid agent or alginate.

PHARMACEUTICAL FORM oral dosage composition containing a proton-pump inhibitor acid sensitive and one or more antacid agents or an alginate IN FORMULATION ...

H Depui，A Hallgren

PHARMACEUTICAL RESEARCH AND BIO-SCIENCE

heart burning and gastro esophagus reflux disease problem which can be overcame by formulating raft forming tablet containing antacid and proton pump inhibitor...

R Laxmi，MG Patel，MB Bhimani

Randomized Controlled Trial Comparing Proton Pump Inhibitor-Based Eradication Regimen versus Low-Cost Eradication Regimen for Patients with Helicobacter pylori with Uninvestigated Dyspepsia

DISCLOSURE This work was supported by TAP Pharmaceutical Products, Inc. Lake Forest, Illinois, and Abbott Laboratories, Abbott Park, Illinois. Background: The impact of various Helicobacter pylori eradication regimens in patients with u...

YK Chen，P Jajodia，L Deguzman，... - 《Journal of Applied Research》

Useful pharmaceutical formulations and methods of making and using the same for inhibiting acid secretion

The present invention comprises at least one acid-labile proton pump inhibitor and at least one antacid, improved bioavailability, chemical stability, physical stability, dissolution profile, disintegration time , safety, and improved hi...

ケイ オルムステッド，ジェラルド ティー. プロール，ウォーレン ホール

A SYSTEMATIC REVIEW AND ECONOMIC ANALYSIS OF THE COST-EFFECTIVENESS OF PROTON PUMP INHIBITOR THERAPY IN NON-ULCER DYSPEPSIA.

Introduction: Proton pump inhibitor (PPI) therapy is an established treatment for gastro-oesophageal reflux disease, but their efficacy in non-ulcer dyspep...

Moayyedi，P.，Delaney，... - Gut

A systematic review and economic analysis of the cost-effectiveness of proton pump inhibitor therapy in non-ulcer dyspepsia

Full dose PPI was assumed to cost 22.75, Iow dose PPI 12.43, antacid 2.48/month, and a GP visit 18. Monte Carlo simulations of 5000 patients were performed using the 95% CI of the meta-analysis data to give stochastic estimates...

P Moayyedi，N Vakil，BC Delaney - 《Gastroenterology》

ORALE, PHARMAZEUTISCHE DARREICHUNGSFORMEN, DIE EINEN PROTONENPUMPENINHIBITOR UND EIN ANTACIDUM ODER ALGINAT ENTHALTEN

An oral pharmaceutical dosage form comprising an acid susceptible proton pump inhibitor and one or more antacid agents or an alginate in a fixed formulatio...

D Helene，H Agneta

Oral pharmaceutical dosage forms comprising a proton pump inhibitor and an antacid agent or alginate

An oral pharmaceutical dosage form comprising an acid susceptible proton pump inhibitor and one or more antacid agents or an alginate in a fixed formulation, wherein the proton pump inhibitor is protected by an enteric coating layer and ...

DEPUI HELENE，HALLGREN AGNETA - WO